Naveen Pemmaraju: Fantastic venue with mix of pre-clinical and clinical presentations focused on novel pathways in heme malignancies

Naveen Pemmaraju shared on LinkedIn:

“I recently gave an invited faculty talk at ISEH – International Society for Experimental Hematology in Chicago on the topic of ‘BH3 mimetics for Myeloid Malignancies – Clincal Perspective.’ I had the wonderful opportunity to speak about my group’s work with BCL2 inhibition in AML & BPDCN as well as BCLXL inhibition in Myelofibrosis. A really fantastic venue with mix of pre-clinical & clinical presentations focused on novel pathways in heme malignancies. Thanks to Caner Saygin for the invitation and providing a unique forum for exchange of ideas.”

Source: Naveen Pemmaraju/LinkedIn

Naveen Pemmaraju is a Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of MDACC Network. He is also the Leukemia Hematology/Oncology Course Director.

His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN and AML.